Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...
Background: Antipsychotic treatment has been linked to hyperprolactinemia, which can lead to increased nonadherence and changes in sexual hormones in both men and women. Here, we evaluate...
Depressive episodes in bipolar I disorder (BP-1) are associated with increased disability, morbidity, and suicide, and have fewer evidence-based treatment options compared to manic episod...
Introduction: Depressive episodes/symptoms of bipolar I disorder (BPD-I) are commonly misdiagnosed as major depressive disorder (MDD). We developed the novel and pragmatic Rapid Mood Scre...
Depression is often the initial and predominant disease presentation in patients with bipolar disorder leading to their frequent misdiagnosis with major depressive disorder. Primary care ...
Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...